<SEC-DOCUMENT>0001171843-23-004422.txt : 20230710
<SEC-HEADER>0001171843-23-004422.hdr.sgml : 20230710
<ACCEPTANCE-DATETIME>20230710060607
ACCESSION NUMBER:		0001171843-23-004422
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20230707
FILED AS OF DATE:		20230710
DATE AS OF CHANGE:		20230710

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		231078152

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_070723.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="margin: 0pt 0; font-size: 18pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 18pt; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="margin: 0pt 0; font-size: 18pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>PURSUANT TO RULE 13a-16 or 15d-16 OF</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>Report on Form 6-K dated July 7, 2023</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>(Commission File No. 1-15024) </B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">____________________</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 18pt; text-align: center"><B>Novartis AG</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">(Name of Registrant)</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>Lichtstrasse 35</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>4056 Basel</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>Switzerland</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">(Address of Principal Executive Offices)</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">____________________</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0 3pt; font-size: 10pt">Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Form 20-F:&nbsp;&#9746;</B></FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Form 40-F:&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>



<P STYLE="margin: 0pt 0 3pt; font-size: 10pt">Indicate by check mark whether the registrant by furnishing the information contained
in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 33%">&nbsp;<IMG SRC="logo.jpg" ALT=""></TD>
  <TD STYLE="width: 34%">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 33%">&nbsp;<IMG SRC="logo2.jpg" ALT="" STYLE="height: 114px; width: 180px"></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0; color: #8D1F1B"><FONT STYLE="font-size: 12pt">MEDIA &amp; INVESTOR RELEASE</FONT><FONT STYLE="font-size: 10pt"><BR>
<BR>
</FONT></P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0; color: #8D1F1B">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Novartis will appeal to U.S. Court of Appeals to uphold validity of Entresto<SUP>&reg;</SUP>
combination patent; maintains 2023 guidance and mid-term outlook</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Ad hoc announcement pursuant to Art. 53 LR</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.15in">&bull;</TD><TD><I>U.S. District Court for the District of Delaware ruled the Entresto (sacubitril / valsartan) &lsquo;combination patent&rsquo; to
be invalid </I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.15in">&bull;</TD><TD><I>Novartis will appeal to the U.S. Court of Appeals for the Federal Circuit to reverse the District Court&rsquo;s ruling</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.15in">&bull;</TD><TD><I>No generic Entresto product has received FDA approval as of today</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.15in">&bull;</TD><TD><I>Pending a final appeal decision and other ongoing litigation involving multiple patents, any launch once generics receive FDA approval
would be &lsquo;at risk&rsquo;</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.15in">&bull;</TD><TD><I>Novartis maintains confidence in short and mid-term growth, maintains 2023 guidance and mid-term outlook</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Basel, July 07, 2023</B> &mdash; Novartis today announced that the U.S. District Court for
the District of Delaware issued a negative decision regarding the validity of a patent covering Entresto and combinations of sacubitril
and valsartan, which expires in 2025 with its pediatric exclusivity. Novartis strongly believes the combination patent is valid and will
appeal to the U.S. Court of Appeals for the Federal Circuit (CAFC) to reverse the District Court&rsquo;s decision.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The company will continue to defend vigorously its intellectual property rights relating to
Entresto, including the combination patent as well as multiple patents covering additional innovations. Currently no generic Entresto
products have tentative or final FDA approval. If approved, any commercial launch of a generic Entresto product prior to the final outcome
of Novartis appeal, or ongoing infringement litigations involving other patents, may be at risk of later litigation developments.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Novartis maintains its confidence in the growth and profitability outlook for both the short
and mid-term, based on the future growth potential of other key brands including Kisqali, Pluvicto, Leqvio, Kesimpta, Scemblix and iptacopan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Despite the potential for earlier-than-expected entry of generic Entresto products in the U.S.,
Novartis maintains its full-year 2023 group guidance<SUP>1</SUP> to investors:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Group Sales expected to grow mid-single digit (in cc)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>Group Core OpInc expected to grow high-single digit (in cc)</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The company also maintains its mid-term outlook of +4% sales growth (in cc) 2022-2027 CAGR,
with 40% Core OpInc margin for Novartis ex-Sandoz.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">Novartis new focused strategy remains on track to deliver growth, driven by key in-market and
launch brands, and a strong pipeline of high value innovative medicines.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Further information </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The U.S. District Court for the District of Delaware issued a negative decision regarding the
validity of U.S. Patent No. 8,101,659, one of the patents listed in the Orange Book for Entresto. This patent, with the associated pediatric
exclusivity, expires on July 15, 2025.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Since October 2019, Novartis has been involved in patent infringement litigation with numerous
Abbreviated New Drug Application (ANDA) filers who are seeking approval to market generic versions of Entresto. Currently, Entresto is
protected by multiple Orange Book-listed patents which expire between 2023 and 2036 (including any pediatric exclusivity). Today&rsquo;s
decision does not impact the separate and ongoing litigation between Novartis and various ANDA filers concerning those and other U.S.
patents:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 19%"><B>U.S. Patent</B></TD>
    <TD STYLE="width: 58%">&nbsp;</TD>
    <TD STYLE="width: 23%"><B>Expiration</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>8,101,659 </TD>
    <TD>combinations of sacubitril and valsartan</TD>
    <TD>July 15, 2025</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>11,096,918 </TD>
    <TD>amorphous forms of sacubitril and valsartan</TD>
    <TD>November 8, 2026</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>9,388,134 </TD>
    <TD>crystalline forms of sacubitril and valsartan</TD>
    <TD>May 8, 2027</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>8,877,938 </TD>
    <TD>crystalline forms of sacubitril and valsartan</TD>
    <TD>November 27, 2027</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>11,058,667 </TD>
    <TD>dosage regimen for treating chronic heart failure</TD>
    <TD>May 9, 2036</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">On July 6, 2023, the U.S. District Court for the Northern District of West Virginia issued a
decision that the proposed generic Entresto products from Mylan Pharmaceuticals Inc. (&ldquo;Mylan&rdquo;) will infringe U.S. Patent Nos.
8,877,938 and 9,388,134.&nbsp; That decision only pertains to Mylan.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Novartis previously entered into settlement agreements with several ANDA filers that will be
able to launch a generic version of Entresto in the United States on an agreed-upon date, or earlier in certain circumstances. Details
of these settlements are confidential.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><SUP>1</SUP> Novartis Group guidance, assuming Sandoz would remain within the Group for the
entire FY 2023, in constant currencies</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Disclaimer</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">This press release contains forward-looking statements within the meaning of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as &ldquo;potential,&rdquo;
&ldquo;can,&rdquo; &ldquo;will,&rdquo; &ldquo;plan,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;seek,&rdquo; &ldquo;look forward,&rdquo; &ldquo;believe,&rdquo; &ldquo;committed,&rdquo; &ldquo;investigational,&rdquo;
&ldquo;pipeline,&rdquo; &ldquo;launch,&rdquo; &ldquo;maintains,&rdquo; &ldquo;confidence,&rdquo; or similar terms, or by express or implied
discussions regarding potential marketing approvals, new indications or labeling for Entresto, regarding potential future revenues from
Entresto, regarding the impact of the decision of the US District Court for the District of Delaware and other ongoing litigation, or
regarding our full-year 2023 guidance and medium-term outlook. You should not place undue reliance on these statements. Such forward-looking
statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown
risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Entresto will
be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can
there be any guarantee of the results and potential impact of the decision of the US District Court for the District of Delaware and other
ongoing litigation. Nor can there be any guarantee that Entresto will be commercially successful in the future or that our 2023 guidance
and medium-term outlook will remain on track. In particular, our expectations regarding Entresto, the impact of the decision of the US
District Court for the District of Delaware and other ongoing litigation, or our 2023 guidance or medium-term outlook could be affected
by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis
of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment,
including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency;
our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and
patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such
as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or
disruptions of our information technology systems, and other risks and factors referred to in Novartis AG&rsquo;s current Form 20-F on
file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does
not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information,
future events or otherwise.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">About Novartis</P>

<P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Novartis is reimagining medicine to improve and extend people&rsquo;s lives. We deliver high-value
medicines that alleviate society&rsquo;s greatest disease burdens through technology leadership in R&amp;D and novel access approaches.
In our quest to find new medicines, we consistently rank among the world&rsquo;s top companies investing in research and development.
About 103,000 people of more than 140 nationalities work together to bring Novartis products to nearly 800 million people around the world.
Find out more at <FONT STYLE="color: blue">https://www.novartis.com</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Novartis is on Twitter. Sign up to follow @Novartis at <B>https://twitter.com/novartisnews</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">For Novartis multimedia content, please visit <B>https://www.novartis.com/news/media-library</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">For questions about the site or required registration, please contact media.relations@novartis.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"># # #</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">
    <P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Novartis Media Relations</P>
    <P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">E-mail: media.relations@novartis.com</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Central</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>North America</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Richard Jarvis</TD>
    <TD COLSPAN="2">+41 79 584 2326</TD>
    <TD>Julie Masow</TD>
    <TD COLSPAN="2">+1 862 579 8456</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font-size: 10pt; margin: 0pt 0">Anja von Treskow</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">Anna Sch&auml;fers</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD>
    <TD COLSPAN="2">
    <P STYLE="font-size: 10pt; margin: 0pt 0">+41 79 392 9697</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">+41 79 801 7267</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD>
    <TD>
    <P STYLE="font-size: 10pt; margin: 0pt 0">Michael Meo</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">Marlena Abdinoor</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD>
    <TD COLSPAN="2">
    <P STYLE="font-size: 10pt; margin: 0pt 0">+1 862 274 5414</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">+1 617 335 9525</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font-size: 10pt; margin: 0pt 0">Switzerland</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">Satoshi Sugimoto</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD>
    <TD COLSPAN="2">
    <P STYLE="font-size: 10pt; margin: 0pt 0">+41 79 619 2035</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3">
    <P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0">Novartis Investor Relations</P>
    <P STYLE="font-size: 10pt; font-weight: bold; margin: 0pt 0"></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">Central investor relations line: +41 61 324 7944</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0"></P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">E-mail: investor.relations@novartis.com</P>
    <P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P></TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Central</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">North America</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Samir Shah</TD>
    <TD>+41 61 324 7944</TD>
    <TD COLSPAN="2">Sloan Simpson</TD>
    <TD>+1 862 345 4440</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Nicole Zinsli-Somm</TD>
    <TD>+41 61 324 3809</TD>
    <TD COLSPAN="2">Parag Mahanti</TD>
    <TD>+1 973 876 4912</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Isabella Zinck</TD>
    <TD>+41 61 324 7188</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 25%">&nbsp;</TD>
    <TD STYLE="width: 24%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 24%">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; font-size: 10pt">
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Novartis AG</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: July
    7, 2023</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ PAUL
    PENEPENT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Penepent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head Group Financial Reporting and
    Accounting</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  L .T# 2(  A$! Q$!_\0
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>5I)\M^9M][6^7ZCAA9?6?K55KFMRI+M>_P _T/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "N 1(# 2(  A$! Q$!_\0
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M+PKYR1'5T#N^P Q2#!SCGY>![GBN8M8+_7-1\+VT7A^\TW^QV#W,]Q%Y:84
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M:+;J-XZ%RW4,>>!@<#W%/O\ Q'XH6/Q-J%OK$<=OI%]Y<=N;5&\Q3)MVEL<
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M>:Z?4A8/SK#DU'5?"<5YX>2\WSMIEI_9DC1J2MQ(_D.3Q\W[QHY#G/WCVXH
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MI7IC$M_+Y)EV1_=0*(Q&%Y;^#/S$YS@AR^+M$;2YM1^V,L,$H@D1X)$F64D
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M,)VDH5D1U(RJGID8ZTM_XPT+3IO*GO6<K")Y&MX))UBB/(>1HU81J1D[F(&
M3T!I+_QEH6FWBV<]Y))<M;K=K%;6TMPS0L6 D C5LKE3D]!QG&1D I67@#2[
M!($CNK]Q#JIU93+*KDSE"C9)7)4[BQR<Y/7'%3ZKX-L]6N-7EDO;V&/5K,6=
MW#$8]K !@KC<A8, Q'!QZ@U)I_C3P_JEY;6UE?F5KH$V\@@D$4Q"[BJ2E=C,
M!G*@DC!! (.(IO%UGIUQ?/JLR6UFM^MA:.(W9IY?*$C ;<Y.=R@8Y*$<DC(
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144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
